Table 1.
Laboratory value | Control group | Study group | P value (between two groups) |
---|---|---|---|
Leucopenia (< 4 K/mcl) | |||
Before treatment | 10/57 (17%) | 0/22 (0%) | 0.06 |
After 1–4 weeks | 11/53 (21%) | 1/15 (7%) | 0.28 |
After 5–8 weeks | 15/54 (28%) | 3/17 (18%) | 0.53 |
After 9–16 weeks | 16/49 (33%) | 3/14 (21%) | 0.52 |
After 17–26 weeks | 10/40 (25%) | 3/13 (23%) | 1 |
Neutropenia (< 1.5 K/mcl) | |||
Before treatment | 2/57 (4%) | 0/22 (0%) | 1 |
After 1–4 weeks | 1/53 (2%) | 0/15 (0%) | 1 |
After 5–8 weeks | 2/54 (4%) | 0/17 (0%) | 1 |
After 9–16 weeks | 5/49 (10%) | 0/14 (0%) | 0.17 |
After 17–26 weeks | 2/40 (5%) | 3/13 (23%) | 0.09 |
Erythrocytopenia (< 4.2 M/mcl) | |||
Before treatment | 31/57 (54%) | 15/22 (68%) | 0.32 |
After 1–4 weeks | 30/53 (57%) | 11/15 (73%) | 0.37 |
After 5–8 weeks | 29/54 (54%) | 10/17 (59%) | 0.78 |
After 9–16 weeks | 23/49 (47%) | 10/14 (71%) | 0.14 |
After 17–26 weeks | 24/40 (60%) | 8/13 (62%) | 1 |
Thrombocytopenia (< 160 K/mcl) | |||
Before treatment | 24/57 (42%) | 8/22 (36%) | 0.08 |
After 1–4 weeks | 20/53 (38%) | 8/15 (53%) | 0.37 |
After 5–8 weeks | 28/54 (52%) | 5/17 (29%) | 0.16 |
After 9–16 weeks | 25/49 (51%) | 9/14 (64%) | 0.54 |
After 17–26 weeks | 21/40 (53%) | 9/13 (69%) | 0.35 |
Lymphocytopenia (< 0.5 K/mcl) | |||
Before treatment | 3/55 (5%) | 3/20 (15%) | 0.33 |
After 1–4 weeks | 15/50 (30%) | 4/16 (25%) | 1 |
After 5–8 weeks | 16/50 (32%) | 1/16 (6%) | 0.05 |
After 9–16 weeks | 10/47 (21%) | 3/13 (23%) | 1 |
After 17–26 weeks | 8/38 (21%) | 0/13 (0%) | 0.17 |